Entropy Technologies, LP Altimmune, Inc. Transaction History

Entropy Technologies, LP

  • $1.34 Trillion
  • Q3 2025

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024
SELL
$5.91 - $10.23 $58,461 - $101,195
-9,892 Reduced 28.65%
24,635 $164 Million
Q1 2024

May 08, 2024
BUY
$8.22 - $13.81 $283,811 - $476,817
34,527 New
34,527 $351 Million

About Altimmune, Inc.

ALT Quotes by TradingView
  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $204M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Entropy Technologies, LP Portfolio

Follow Entropy Technologies, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Entropy Technologies, LP, based on Form 13F filings with the SEC.

News

Stay updated on Entropy Technologies, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email